Online inquiry

IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15902MR)

This product GTTS-WQ15902MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1B gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3553
UniProt ID P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15902MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9727MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ3482MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ9533MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ1489MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ10873MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ2366MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ411MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ9742MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JR-141
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW